Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: Results from a multicentered, placebo-controlled clinical trial

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1910-1924

  Mallery, Susan R ^a,b   Tong, Meng ^a   Shumway, Brian S ^c   Curran, Alice E ^d   Larsen, Peter E ^a   Ness, Gregory M ^a   Kennedy, Kelly S ^a   Blakey, George H ^d   Kushner, George M ^c   Vickers, Aaron M ^c   Han, Brian ^a   Pei, Ping ^a   Stoner, Gary D ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIVE AGENT; GENOMIC DNA; PLACEBO; GEL;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA ISOLATION; DRUG EFFICACY; DRUG SAFETY; ENZYME METABOLISM; FEMALE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATINOCYTE; MALE; MICRODISSECTION; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASPBERRY; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ADMINISTRATION AND DOSAGE; CHEMISTRY; CLINICAL TRIAL; FRUIT; GEL; MOUTH NEOPLASMS; PATHOLOGY; PHYTOTHERAPY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; FEMALE; FRUIT; GELS; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PHYTOTHERAPY;

EID: 84898727207     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3159     Document Type: Article

References (42)

1. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009;45:301-8.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.
3. Ho MW, Field EA, Field JK, Risk JM, Rajlawat BP, Rogers SN, et al. Outcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: rationale for monitoring premalignant oral lesions in a multidisciplinary clinic. Br J Oral Maxillofac Surg 2013;51:594-9.
4. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, et al. Survival following primary surgery for oral cancer. Oral Oncol 2009;45:201-11.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
6. Rogers SN, Scott J, Chakrabati A, Lowe D. The patients' account of outcome following primary surgery for oral and oropharyngeal cancer using a 'quality of life' questionnaire. Eur J Cancer Care 2008;17:182-8.
7. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563-8. (Pubitemid 14182737)
8. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:321-9.
9. Arnaoutakis D, Bishop J, Westra W, Califano JA. Recurrence patterns and management of oral cavity premalignant lesions. Oral Oncol 2013;49:814-7.
10. Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, Kim ES, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
11. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res 2009;2:931-41.
12. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14:2095-101. (Pubitemid 351551121)
13. Saba N, Hurwitz SJ, Kono S, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase 1b and pharmacokinetic study. Cancer Prev Res 2013 Oct 3. [Epub ahead of print].
14. Mallery SR, Zwick JC, Pei P, Tong M, Larsen PE, Shumway BS, et al. Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions. Cancer Res 2008;68:4945-57.
15. Shumway BS, Kresty LA, Larsen PE, Zwick JC, Lu B, Fields HW, et al. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin Cancer Res 2008;14:2421-30. (Pubitemid 351551076)
16. Wang LS, Stoner GD. Anthocyanins and their role in cancer prevention. Cancer Lett 2008;269:281-90.
17. Xue H, Aziz RM, Sun N, Cassady JM, Kamendulis LM, Xu Y, et al. Inhibition of cellular transformation by berry extracts. Carcinogenesis 2001;22:351-6. (Pubitemid 32175527)
18. Kresty LA, Morse MA, Morgan C, Carlton PS, Lu J, Gupta A, et al. Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res 2001;61:6112-9. (Pubitemid 32762547)
19. Mallery SR, Budendorf DE, Larsen MP, Pei P, Tong M, Holpuch AS, et al. Effects of human oral mucosal tissue, saliva, and oral microflora on intraoral metabolism and bioactivation of black raspberry anthocyanins. Cancer Prev Res 2011;4:1209-21.
20. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:188-91.
21. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996;56:3331-7. (Pubitemid 26242985)
22. Stoner GD, Wang LS, Zikri N, Chen T, Hecht SS, Huang C, et al. Cancer prevention with freeze-dried berries and berry components. Semin Cancer Biol 2007;17:403-10. (Pubitemid 47376814)
23. Hecht SS, Huang C, Stoner GD, Li J, Kenney PMJ, Sturla SJ, et al. Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NFκB and AP-1 activity. Carcinogenesis 2006;27:1617-26. (Pubitemid 44288051)
24. Stoner GD, Wang LS, Casto BC. Laboratory and clinical studies of cancer chemoprevention by antioxidants in berries. Carcinogenesis 2008;29:1665-74.
25. Webb MR, Min K, Ebeler SE. Anthocyanin interactions with DNA: intercalation, topoisomerase I inhibition and oxidative reactions. J Food Biochem 2008;32:576-96.
26. Terahara N, Matsui T. Structure and Functionalities of Acylated Anthocyanins. In: Shibamoto T, editors. ACS Symposium Series, Functional Food and Health. Washington DC: Oxford University Press; 2008. p. 90-101.
27. Huang C, Zhang D, Li J, Tong Q, Stoner GD. Differential inhibition of UV-induced activation of NF kappa B and AP-1 by extracts from black raspberries, strawberries, and blueberries. Nutr Cancer 2007;58:205-12. (Pubitemid 47328772)
28. Walle T, Browning AM, Steed LL, Reed SG, Walle UK. Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J Nutr 2005;135:48-52. (Pubitemid 40094319)
29. Woodward GM, Needs PW, Kay CD. Anthocyanin-derived phenolic acids form glucuronides following simulated gastrointestinal digestion and microsomal glucuronidation. Mol Nutr Food Res 2011;55:378-86
30. Swida A, Woyda-Ploszczyca A, Jarmuszkiewicz W. Redox state of quinone affects sensitivity of Acanthamoeba castellanii mitochondrial uncoupling protein to purine nucleotides. Biochem J 2008;413:359-67.
31. Rodrigo KA, Rawal Y, Renner RJ, Schwartz SJ, Tian Q, Larsen PE, et al. Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries. Nutr Cancer 2006;54:58-68. (Pubitemid 44141336)
32. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215.
33. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125:1083-9. (Pubitemid 29473370)
34. Gao S, Basu S, Yang G, Deb A, Hu M. Oral bioavailability challenges of natural products used in cancer chemoprevention. Pro in Chem 2013;25:1553-74.
35. Ugalde CM, Liu Z, Ren C, Chan KK, Rodrigo KA, Ling Y, et al. Distribution of anthocyanins delivered from a bioadhesive black raspberry gel following topical intraoral application in normal healthy volunteers. Pharm Res 2009;26:977-86.
36. Graveland AP, Bremmer JF, de Maaker M, Brink A, Cobussen P, Zwart M, et al. Molecular screening of oral precancer. Oral Oncol 2013;8:1129-35.
37. Kresty LA, Mallery SR, Knobloch TJ, Li J, Lloyd M, Casto BC, et al. Frequent alterations of p16INK4a and p14ARF in oral proliferative verrucous leukoplakia. Cancer Epidemiol Biomarkers Prev 2008;17:3179-87.
38. Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, et al. Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev Res 2012;5:1081-9.
39. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5. (Pubitemid 26191956)
40. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90:1545-51. (Pubitemid 28535719)
41. Bremmer JF, Graveland AP, Brink A, Braakhuis BJM, Dirk J, Kuik DJ, et al. Screening for oral precancer with noninvasive genetic cytology. Cancer Prev Res 2009;2:128-33.
42. William WN Jr. Oral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol 2012;24:205-10.